Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17122442 | 0.69 | ATM (0.37) | ATMDAO | |
| SCHEMBL5111536 | 0.68 | MAOA (0.46) | — | |
| SCHEMBL31607496 | 0.66 | MAOA (0.33) | ATM | |
| Phenoxathiine SCHEMBL7922 | 0.65 | MAOA (0.42) | ATM | |
| Phenoxathiine SCHEMBL29373698 | 0.65 | MAOA (0.42) | ATM | |
| Phenoxathiine SCHEMBL29396568 | 0.65 | MAOA (0.42) | ATM | |
| Phenoxathiine SCHEMBL5699627 | 0.64 | MAOA (0.40) | ATM | |
| SCHEMBL19205828 | 0.64 | AHR (0.41) | ATM | |
| Phenoxathiine SCHEMBL5970725 | 0.64 | MAOA (0.40) | ATM | |
| Phenoxathiine SCHEMBL10512948 | 0.64 | MAOA (0.40) | ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4326736-A1 | MORPHOLOGICAL MARKER STAINING | Ventana Medical Systems, Inc. (US) | 2024-02-28 | — | — | EP | claimed |
| US-20240043904-A1 | MORPHOLOGICAL MARKER STAINING | VENTANA MEDICAL SYSTEMS, INC. | 2024-02-08 | — | — | US | claimed |
| WO-2022223137-A1 | MORPHOLOGICAL MARKER STAINING | VENTANA MEDICAL SYSTEMS, INC. (US) | 2022-10-27 | — | — | WO | claimed |
| EP-4740016-A1 | BRIGHTFIELD TRIPLEX IMMUNOHISTOCHEMISTRY ASSAY FOR EVALUATING THE COLOCALIZATION OF THE ER, PR, AND KI-67 BIOMARKERS IN CELLS | Ventana Medical Systems, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260016475-A1 | MATERIALS AND METHODS FOR EVALUATION OF ANTIGEN PRESENTATION MACHINERY COMPONENTS AND USES THEREOF | VENTANA MED SYST INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4639170-A1 | MATERIALS AND METHODS FOR EVALUATION OF ANTIGEN PRESENTATION MACHINERY COMPONENTS AND USES THEREOF | Ventana Medical Systems, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| WO-2025014787-A1 | BRIGHTFIELD TRIPLEX IMMUNOHISTOCHEMISTRY ASSAY FOR EVALUATING THE COLOCALIZATION OF THE ER, PR, AND KI-67 BIOMARKERS IN CELLS | VENTANA MEDICAL SYSTEMS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| WO-2024137817-A1 | MATERIALS AND METHODS FOR EVALUATION OF ANTIGEN PRESENTATION MACHINERY COMPONENTS AND USES THEREOF | VENTANA MEDICAL SYSTEMS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| EP-4326736-A1 | MORPHOLOGICAL MARKER STAINING | Ventana Medical Systems, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20240043904-A1 | MORPHOLOGICAL MARKER STAINING | VENTANA MEDICAL SYSTEMS, INC. | 2024-02-08 | — | — | US | disclosed |
| EP-4204398-A2 | CONJUGATES INCLUDING A DETECTABLE MOIETY | Ventana Medical Systems, Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20230192658-A1 | CONJUGATES INCLUDING A DETECTABLE MOIETY | VENTANA MEDICAL SYSTEMS, INC. | 2023-06-22 | — | — | US | disclosed |
| CN-115989221-A | Conjugates comprising a detectable moiety | 文塔纳医疗系统公司 | 2023-04-18 | — | — | CN | disclosed |
| WO-2022223137-A1 | MORPHOLOGICAL MARKER STAINING | VENTANA MEDICAL SYSTEMS, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022043491-A2 | CONJUGATES INCLUDING A DETECTABLE MOIETY | VENTANA MEDICAL SYSTEMS, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192658-A1 | CONJUGATES INCLUDING A DETECTABLE MOIETY | CD2BP2, CD47, CD44 | ATM 3663/4885DAO 2221/4885 |
| US-20260016475-A1 | MATERIALS AND METHODS FOR EVALUATION OF ANTIGEN PRESENTATION MACHINERY COMPONENTS AND USES THEREOF | TAP1, TAP2, MICA | ATM 2474/4885DAO 3867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.